A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients.
Level 2 - randomized trial
Individual randomized controlled trial.
PubMed 37767025 · doi:10.12688/f1000research.138477.1
What was done
A randomized, controlled, open-label trial evaluated the add-on efficacy and safety of PeaNoc XL tablets in 72 arthritis patients aged 18 to 60 years (from 155 screened). Participants were randomly assigned to receive either standard therapy alone (Group A, n=36) or standard therapy plus PeaNoc XL 400 mg (two tablets once daily after food; Group B, n=36) for 12 weeks.
What was found
The addition of PeaNoc XL to standard therapy significantly reduced circulating inflammatory markers: TNF-α (P<0.01), IL-1β (P<0.001), IL-6 (P<0.01), and CRP (P<0.01). No notable differences from baseline were observed in the standard therapy alone group. Specific absolute values for inflammatory biomarkers and numerical outcomes for pain scores, joint stiffness, and physical stiffness were not reported in the abstract.
Why it matters
This study provides preliminary randomized trial evidence suggesting that PeaNoc XL may reduce inflammatory biomarkers when used as an adjunct to standard arthritis treatment.
Limits
The study was open-label without blinding, introducing risk of bias. The sample size was small (n=72), with a high exclusion rate (83 of 155). The abstract reports p-values but no baseline or post-treatment numbers, confidence intervals, adverse events, or definitions of the standard therapy regimen.
Cited by
- supports Palmitoylethanolamide (PEA) relieves pain and reduces inflammation following an injury.